Arcturus Therapeutics HoldingsARCT +7.41%56 Net Current Asset Value is $5.73 as of Mar. 2026, which is 80% above its 10-year median of 3.18. GuruFocus rates ARCT with a GF Score™ of 56/100 and a GF Value™ of $4.15 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 946 Biotechnology companies, Arcturus Therapeutics Holdings ranks better than 89.32% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Arcturus Therapeutics Holdings's Net Current Asset Value or its related term are showing as below:
ARCT'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.71 Med: 3.18 Max: 367.5
Current: 1.29
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Arcturus Therapeutics Holdings was 367.50. The lowest was 0.71. And the median was 3.18.
ARCT's Price-to-Net-Current-Asset-Value is ranked better than 89.32% of 946
companies
in the Biotechnology industry
Industry Median: 4.87
vs ARCT: 1.29
Arcturus Therapeutics Holdings (NAS:ARCT) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Arcturus Therapeutics Holdings Net Current Asset Value Related Terms
Arcturus Therapeutics Holdings Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings Net Current Asset Value Chart
ARCT vs MDWD, UNCY, EQ: Net Current Asset Value Comparison
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $5.73 mean?
Arcturus Therapeutics Holdings (ARCT) has a Net Current Asset Value of $5.73 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Arcturus Therapeutics Holdings and its competitors. This is 80% above median its historical median of 3.18. Over the past decade, Arcturus Therapeutics Holdings' Net Current Asset Value has ranged from 0.71 to 367.50. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #101 out of 946 companies in the Biotechnology industry, placing it in the top 10.7%.
Is Arcturus Therapeutics Holdings' Net Current Asset Value too high?
Arcturus Therapeutics Holdings' current Net Current Asset Value of $5.73 is 80% above median its 10-year median of 3.18. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 367.50. The Biotechnology industry median Net Current Asset Value is 4.87. Arcturus Therapeutics Holdings' value of $5.73 is 17.7% above this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #101 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Net Current Asset Value compare to MDWD and UNCY?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #101 out of 946 companies for Net Current Asset Value. This places Arcturus Therapeutics Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.87. Arcturus Therapeutics Holdings' value of $5.73 is 17.7% above this benchmark. Historically, Arcturus Therapeutics Holdings' own Net Current Asset Value has ranged from 0.71 to 367.50 over the past decade. While the company's 10-year median is 3.18 vs. the industry median of 4.87, Arcturus Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.87, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current Net Current Asset Value of $5.73 is 17.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Arcturus Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current Net Current Asset Value is $5.73, which is 80% above median its own 10-year median of 3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.15, compared to a current price of $7.39 — trading 78.1% above its estimated fair value. The current Net Current Asset Value is $5.73, which is 80% above median its 10-year median of 3.18 and 17.7% above the Biotechnology industry median of 4.87. Arcturus Therapeutics Holdings' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Net Current Asset Value is $5.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued.
The current stock price of $7.39 is trading 78.1% above its estimated GF Value™ of $4.15.
GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.
Key valuation signals for ARCT:
Net Current Asset Value: $5.73 (80% above median its 10-year median of 3.18)
GF Value™: $4.15 vs. price of $7.39 (78.1% above fair value)
Industry Position: 17.7% above the Biotechnology median (#101 of 946)
No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcturus Therapeutics Holdings Business Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
56GF Score
Get the complete analysis for ARCT
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCT has been successfully added to your 
